Review in clinical application and challenges of denosumab in osteoporosis and neoplastic bone disease
- VernacularTitle:地舒单抗在骨质疏松症和肿瘤性骨病中的临床应用及挑战综述
- Author:
Ningning ZHANG
1
;
Lu YU
;
Liping LI
;
Hongwei JIANG
Author Information
- Publication Type:Research Article
- Keywords: receptor activator of NF-kappa B ligand; Denosumab; osteoporosis; bone tumor; duration of treatment
- From: Journal of Clinical Medicine in Practice 2024;28(11):144-148
- CountryChina
- Language:Chinese
- Abstract: Denosumab (Dmab) is a receptor activator of NF-kappaB ligand (RANKL) inhibitor with better efficacy and safety. Dmab has been approved to treat patients with osteoporosis (OP), giant cell tumor of bone (GCTB), multiple myeloma (MM) and bone metastases from solid tumors. However, in clinical practice, Dmab is faced with problems such as drug duration, drug withdrawal sequence and local recurrence. This article reviewed the clinical application and challenges of Dmab in OP and neoplastic bone disease, aiming to provide evidence for clinical treatment.
